natgillin/translations-raw huggingface dataset:
The composition of claim 1, wherein said single-stranded RNAs or mRNAs encodes at least one protein selected from the group consisting of: a protein that reduces or suppresses an innate immune response comprising interferon (IFN) production or response; B18R protein; Vaccinia virus E3L or K3L protein; erythropoietin (EPO); firefly luciferase, Renilla luciferase, bacterial beta-galactosidase (lacZ); and green fluorescent protein (GFP). 
Obrađeni sastav ribonukleinske kiseline prema bilo kojem od zahtjeva 1-3, naznačen time što navedeni sastav ribonukleinske kiseline ili ssRNA ili mRNA kodira najmanje jedan protein odabran iz skupine koja se sastoji od: proteina koji smanjuje ili suzbija urođeni imuni odgovor koji sadrži proizvodnju interferona (IFN). ili odgovora, poput mRNA koja kodira B18R protein ili E3L ili K3L protein vaccinia virusa, ili funkcionalni fragment ili varijantu bilo kojeg od njih.
In a preferred embodiment of the pharmaceutical composition as disclosed the adjuvant is selected from the group consisting of colony-stimulating factors, such as Granulocyte Macrophage Colony Stimulating Factor (GM-CSF, sargramostim), imiquimod, resiquimod, and interferon-alpha. 
Farmaceutski sastav prema zahtjevu 5, gdje je adjuvans odabran iz skupine koja sadrži čimbenike za poticanje kolonija kao što su čimbenik za poticanje granulocitnih i makrofagnih kolonija (GM-CSF), odnosno imikvimod ili resikvimod.
Preparation of Nebivolol HCl (I) Using Isopropyl Alcohol as Reaction Solvent and Purification of Nebivolol HCl (I) ml of isopropyl alcohol and 3.5 g of hydrochloric acid were added to 10 g of nebivolol base (IX) and the reaction mixture was stirred for 4 h at 28-32° C. The material was filtered, washed with 10.0 ml of isopropyl alcohol and filtered to dryness. 
Dobivanje nebivolol HCI (1) uporabom izopropil alkohola kao reakcijskog otapala i pročišćavanje nebivolol HCI (I) 70 ml izopropil alkohola 1 3,5 g klorovodične kiseline dodano je u 10 g nebivolol baze (TX) te je reakcijska mješavina miješana tijekom 4 sata na 28-32 *C, Materijal je profiltriran, ispran s 10,0 ml izopropil alkohola te filtriran do suhoće.
The heterodimeric antibody of claim 7, wherein the CH3 domain of the first heavy chain further comprises a substitution, as compared to wildtype, of the amino acid residue at position 351 by a positively charged amine acid residue. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što navedeni prvi polipeptidni lanac koji sadrži CH3 domenu dalje sadrži ostatak lizina (K) na aminokiselinskom položaju 351 u skladu s EU sustavom numeracije.
The composition for use according to any one of claims 1-5, further comprising an agent for facilitating transfer of the RNA molecule to an intracellular compartment of a target cell, optionally wherein said target cell is selected from the group consisting of hepatocytes, epithelial cells, hematopoietic cells, epithelial cells, endothelial cells, lung cells, bone cells, stem cells, mesenchymal cells, neural cells, cardiac cells, adipocytes, vascular smooth muscle cells, cardiomyocytes, skeletal muscle cells, beta cells, pituitary cells, synovial lining cells, ovarian cells, testicular cells, fibroblasts, B cells, T cells, reticulocytes, leukocytes, granulocytes and tumor cells. 
Sastav za upotrebu prema bilo kojem od patentnih zahtjeva 1-5, koji dalje sadrži agens za olakšavanje prijenosa RNA molekula u intracelularni odjeljak ciljne stanice, opcionalno pri čemu je navedena ciljna stanica izabrana iz grupe koja se sastoji od hepatocita, epitelnih stanica, hematopoetskih stanica, epitelnih stanica, endotelnih stanica, stanica pluća, stanica kostiju, matičnih stanica, mezenhimskih stanica, živčanih stanica, stanica srca, adipocita, stanica vaskularnih glatkih mišića, kardiomiocita, stanica skeletnih mišića, beta stanica, stanica hipofize, stanica sinovijalne ovojnice, stanica jajnika, stanica testisa, fibroblasta, B stanica, T stanica, retikulocita, leukocita, granulocita i tumorskih stanica.
Source of starting materials 3-chloropropanoyl chloride and ethyl cyanoacetate were obtained commercially from Sigma-Aldrich Company Ltd., The Old Brickyard, New Road, Gillingham, Dorset SP8 4XT, United Kingdom, or synthesised by standard methods. 
Izvor polazišnih materijala 3-kloropropanoil klorid i etil cijanoacetat dobiveni su komercijalno od Sigma-Aldrich Company Ltd., The Old Brickyard, New Road, Gillingham, Dorset SP8 4XT, Ujedinjeno kraljevstvo, ili sintetizirani standardnim metodama.
The pharmaceutical composition according to claim 23 in form of a tablet, capsule, powder, pellet, suspension, emulsion, cream, gel, ointment or paste. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 23, naznačen time što je u obliku tablete, kapsule, praška, peleta, suspenzije, emulzije, kreme, gela, masti ili paste.
The process according to any of claims 10 to 12, wherein the compound of formula (VI) is obtained by reacting a compound of formula (VII) or a hydrohalogenide thereof with trimethyl 1,1,2-ethantricarboxylate in the presence of a fourth base. 
Postupak sukladno patentnom zahtjevu 9 do 11, naznačeno time što spoj formule (VI) je dobiven reakcijom spoja formule (VII) ili njegovog hidrohalogenida [image] s trimetil 1,1,2-etantrikarboksilatom uz prisutnost četvrte osnove.
The process according to claim 8 wherein said compound of formula III is present at an amount of 5 moles per mole of compound of formula II. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što je navedeni spoj Formule III prisutan u količini od 5 mol po molu spoja Formule II.
or an agriculturally acceptable salt or ester thereof, and (b) propyzamide. 
(D ili njegove agrikulturno prihvatljive soli ili ester (b) 1 propizamida, gdje pripravak pokazuje sinergizam.
The invention further concerns any of the above-described isolated antibodies or immunoreactive fragments thereof, wherein the antibody binds to B7-H3 that is internalized upon binding to B7-H3 expressed on the surface of a cancer cell. 
Molekula koja se veže na B7-H3 u skladu s patentnim zahtjevom 1 ili 2, naznačena time što se navedena molekula koja se veže na B7-H3 veže na B7-H3 koji se endogeno eksprimira na površini stanice raka.
Recombinant Expression of Molecules of the Invention 
Datum podnošenja europske prijave patenta:
A monoclonal antibody or functional part thereof, which antibody or functional part thereof is capable of recognizing and binding an epitope of amyloid beta and: is produced by hybridoma cell line FP 12H3-G2, deposited on December 01, 2005 as DSM ACC2751; or 
Monoklonsko protutijelo, ili njegov funkcionalan dio, u skladu s patentnim zahtjevom 1, naznačeno time što ga proizvodi hibridomna stanična linija FP 12H3-C2, deponirana 01. prosinca 2005. kao DSM ACC2750.
wherein the lubricant is present in an amount ranging from 0.1 to 3 weight percent relative to the total weight of the solid pharmaceutical composition; and 
Postupak prema zahtjevu 18, naznačen time da se ukupna težina oralnog oblika doziranja sastoji od 0.1-10 tež.% sredstva za podmazivanje.
a filtration system in fluid communication with the mobile suctioning system, wherein the filtration system receives the portion of water suctioned by the mobile suction system; and 
sustav za filtriranje (40) u fluidnoj vezi s pokretnim usisnim uređajem (42), pri čemu sustav za filtriranje (40) prima dio vode koji je usisan pomoću pokretnog usisnog sustava;
reacting the 5-aryl or 5-heteroaryl-3-hydroxy-2-carboxypyridine formed in step (C) with a compound having the formula: 
D) reakciju 5-aril ili 5-heteroaril-3-hidroksi-2-karboksipiridina formiranog u koraku (C) sa spojem formule: i
After isolation, the solvent may be removed from Form D. The solvent is removed by vacuum drying or in an inert gas flow, whereby the relative air humidity in all process steps is less than 50%, and preferably less than 40%. 
poželjno izopropanolu, da bi se stvorio Oblik E, a krutina se izolira filtracijom; i ostatak otapala se ukloni iz krutine ili vakuumskim sušenjem ili upuhivanjem suhog plina.
Solid dosage forms for oral administration include capsules, tablets, powders, and granules. 
Farmaceutski sastav prema zahtjevu 1, pri čemu je kruti dozni oblik kapsula, tableta, prašak, ili granula.
As used throughout the disclosure, the term d95 means that 95% of the particles (based on volume) are smaller than or equal to the indicated size. 
Kako se rabi kroz tekst, izraz d95 znači da je 95% čestica (na osnovu volumena) manje od ili jednako navedenoj veličini.
The sealing member 11 is thus compressed by the bottom 28 of the enclosing member 9 and (see figure 14) secured in place by the upper end of the circumferential side wall 25 of the enclosing member 9. 
Element za nepropusno zatvaranje 11 je na taj način stlačen dnom elementa 28 koji obuhvaća čahuru 9 1 (vidi sliku 14) učvršćen je na svojem mjestu gornjim krajem obodne strane stijenke 25 elementa za obuhvaćanje čahure 9.
The MDO film according to any one of statements 21 to 23, wherein the MDO film has a tensile creep in the machine direction of about 0.10% to about 0.50% per µm thickness of the film, as measured in accordance with ISO 899-1-2003 with following conditions: sample width of 15 mm, grip distance of 100 mm, a load of 2300 g, for 24 hours, and at 23°C. 
Pakirani proizvod u skladu s bilo kojim od patentnih zahtjeva 9, 11 ili 12, ili MDO film u skladu s bilo kojim od patentnih zahtjeva 10 do 12, naznačen time, da MDO film ima vrijednost vlačnog puzanja u smjeru stroja od oko 0,10% do oko 0,50% po um debljine filma, izmjereno u skladu s ISO 899-1-2003 pri sljedećim uvjetima: širina uzorka od 15 mm, udaljenost prihvata od 100 mm, opterećenje od 2300 g, 24 sata 1 na 23 *C.
The method of claim 1, wherein the autoimmune disease is uveitis, type I diabetes, rheumatoid arthritis, an inflammatory bowel disease, or multiple sclerosis. 
Spoj za uporabu prema zahtjevu 7, ili njegova farmaceutski prihvatljiva sol, naznačen/a time, da autoimuna bolest je uveitis, dijabetes tipa 1, reumatoidni artritis, upalna bolest crijeva ili multipla skleroza.
The process of claim 6, wherein the compound of Formula (III) is prepared by the steps of: reacting 3-nitro-N-ethoxycarbonyl-phthalimide with a glutamine ester having Formula (VIII): or an acid salt thereof in the presence of a first catalyst to form a compound of Formula (IX) or a salt, solvate, polymorph or stereoisomer thereof: and 
Postupak dobivanja spoja Formule (I): [image], ili njegove farmaceutski prihvatljive soli, solvata, polimorfa ili stereoizomera, naznačen time što se sastoji u koraku reakcije 3-aminoftalne kiseline, ili njezine soli, sa spojem 3-aminoglutarimida Formule (X), ili njegovom solju:
The use of a compound of any of the claims 1 to 12 as a medicament. 
Formulacija za inhaliranje bez propelanta koja sadrži spoj opće formule (II) kako je definiran u patentnom zahtjevu 1.
chlorinating a compound represented by the formula: by adding a chlorinating agent thereto in a solvent; 
kloriranje spoja predstavljenog formulom: [image] tako što mu se dodaje sredstvo za kloriranje u otapalu;
The compound of claim 14 wherein R1 is optionally substituted azaindole, optionally substituted benzofuran, optionally substituted benzothiazole, optionally substituted benzoxazole, optionally substituted dihydropyrroloimidazole, optionally substituted furan, optionally substituted imidazole, optionally substituted imidazoxazole, optionally substituted imidazopyrazine, optionally substituted imidazopyridine, optionally substituted indazole, optionally substituted indole, optionally substituted isoquinoline, optionally substituted isothiazole, optionally substituted isoxazole, optionally substituted oxadiazole, optionally substituted oxazole, optionally substituted pyrazole, optionally substituted pyridine, optionally substituted pyrimidine, optionally substituted pyrazolopyridine, optionally substituted pyrrole, optionally substituted quinoline, optionally substituted quinazoline, optionally substituted thiazole, or optionally substituted thiophene. 
Spoj u skladu s patentnim zahtjevom 14, naznačen time, da R1 je po izboru supstituirani azaindol, po izboru supstituirani benzofuran, po izboru supstituirani benzotiazol, po izboru supstituirani benzoksazol, po izboru supstituirani dihidropiroloimidazol, po izboru supstituirani furan, po izboru supstituirani imidazol, po izboru supstituirani imidazoksazol, po izboru supstituirani imidazopirazin, po izboru supstituirani imidazoporidin, po izboru supstituirani indazol, po izboru supstituirani indol, po izboru supstituirani izokinolin, po izboru supstituirani izotiazol, po izboru supstituirani izoksazol, po izboru supstituirani oksadiazol, po izboru supstituirani oksazol, po izboru supstituirani pirazol, po izboru supstituirani piridin, po izboru supstituirani pirimidin, po izboru supstituirani pirazolopiridin, po izboru supstituirani pirol, po izboru supstituirani kinolin, po izboru supstituirani kinazolin, po izboru supstituirani tiazol ili po izboru supstituirani tiofen.
Y is N or CH. The compound of item 7, wherein X is hydrogen and Y is CH. The compound of item 7, wherein X is hydrogen and Y is N. 
YjeNili CH. Spoj u skladu s patentnim zahtjevom 7, pri čemu je (1) X vodik i Y CH; (11) X je vodik i Y je N; (111) X je klor1 Y je
A rat trap according to one of the claims 1 or 2, characterised in that the second sensor is adapted for sensing visible light. A rat trap according to one of the claims 1, 2 or 3, characterised in that the control means is adapted for deactivating the killing means when the second sensor senses light above a given intensity. 
Zamka za štakore prema zahtjevu 2, naznačena time da zamka za štakore obuhvaća elektronska sredstva za bežični prijenos radnih parametara do jedinice prijemnika na npr. razini tla. Zamka za štakore prema jednom ili više prethodnih zahtjeva, naznačena time da izmjena baterije kao i nadzor zamke je lako dostupan bez potrebe za uklanjanjem kućišta za zamku.
For two drugs that act of independent way: EPMATHMARKEREP where A1 is the rate of animals with thrombotic occlusion in the treatment group A1; A2 is the rate of animals with thrombotic occlusion in the treatment group A2; and B is the rate of animals with thrombotic occlusion in the control group 
Frakcijska inhibicija = [1 - (A,/B x A2/B)] x 100 gdje A, je broj životinja s tromboznom okluzijom u liječenoj skupini A;; A2 je broj životinja s tromboznom okluzijom u liječenoj skupini A;; i B je broj životinja s tromboznom okluzijom u kontroloj skupini.
Suitable methods for conjugating a targeting peptide to a recombinant lysosomal enzyme include modifying the amino (N)-terminus and one or more lysine residues on a recombinant human lysosomal enzyme using a first crosslinking agent to give rise to a first crosslinking agent modified recombinant human lysosomal enzyme, modifying the amino (N)-terminus of a short extension linker region preceding a variant IGF-2 peptide using a second crosslinking agent to give rise to a second crosslinking agent modified variant IGF-2 peptide, and then conjugating the first crosslinking agent modified recombinant human lysosomal enzyme to the second crosslinking agent modified variant IGF-2 peptide containing a short extension linker. 
modificiranje amino (N)-terminalnog kraja i jednog ili više lizinskih ostataka na rekombinantnom ljudskom lizosomalnom enzimu korištenjem prvog sredstva za umrežavanje što dovodi do rekombinantnog ljudskog lizosomalnog enzima modificiranog prvim sredstvom za umrežavanje; ii. - modificiranje prve aminokiseline od kratke proširujuće poveznice na amino (N)- terminalnom kraju na varijantu IGF-2 peptida korištenjem drugog sredstva za umrežavanje što dovodi do varijante IGF-2 peptida modificirane drugim sredstvom za umrežavanje; i iii. konjugiranje prvog sredstva za umrežavanje-modificiranog rekombinantnog ljudskog lizosomalnog enzima na drugo sredstvo za umrežavanje-modificirane varijante IGF-2 peptida koja sadrži kratku proširujuću poveznicu; ili
Said oak boards were obtained by the gluing of shorter pieces of wood of oak 10 which were freshly sawn from green lumber, by means of edge gluing the ends with a polyurethane adhesive (product Prefere 6000, company Dynea). 
Navedene ploče od hrasta bile su dobivene lijepljenjem kraćih komada drva od hrasta 10 koji su bili svježe ispiljeni od zelenog debla, uz pomoć rubnog lijepljenja krajeva s poliuretanskim ljepilom (proizvod Prefere 6000, kompanija Dynea).
A further aspect of the invention provides pharmaceutical preparations comprising the orthorhombic crystalline form of asenapine maleate in association with one or more pharmaceutically acceptable additives or excipients. 
Sljedeći aspekt ovog izuma omogućuje farmaceutske pripravke koji sadrže ortorombski kristalni oblik asenapin maleata povezanog s jednim ili više farmaceutski prihvatljivih dodataka ili ekscipijenata.
the split information is generated to indicate a non-split for the coding unit of a current depth, at least one prediction unit is determined by dividing a height and a width of the coding unit of the current depth or to be a data unit of the same size as the coding unit of the current depth and prediction is performed on the coding unit of the current depth based on the at least one prediction unit, and 
kada informacija o podijeli označava da se kodirajuća jedinica trenutne dubine ne može više dijeliti, dekoder (230) je podešen da određuje veći broj jedinica predviđanja u kodirajućoj jedinici trenutne dubine, provodi među predviđanje na mnoštvu jedinica predviđanja, određuje jednu ili više jedinica transformacije u kodirajućoj jedinici trenutne dubine i provodi inverznu transformaciju na jedinicama transformacije.
Each dosage unit contains suitably from 20 µg to 1000 µg and preferably from 50 µg to 300 µg of an M3 antagonist according to the invention or a pharmaceutical acceptable salt thereof and 1 µg to 300 µg, and preferably from 5 µg to 100 µg of a B2-agonist according to the invention. 
Svaka jedinica za doziranje sadrži prikladnu količinu od 20 ug do 1000 ug i poželjno od 50 ug do 400 ug M3 antagonista sukladno predmetnom izumu ili njegove farmaceutske prihvatljive soli i 1 ug do 800 ug, poželjno od 20 ug do 500 ug kortikosteroida sukladno predmetnom izumu. HR P20090107 T3
1418, the disclosure of which is hereby incorporated by reference. The compounds of the general formula (I) having geometrical and stereoisomers are also a part of the invention. 
Spojevi opće formule (I) koji imaju geometrijske izomere i stereoizomere također su dio ovog izuma, Prema daljnjem cilju, ovaj izum također se odnosi na postupke dobivanja spojeva formule (1).
The method of claim 1, wherein said autoimmune disease is a skin disorder, multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, type I diabetes, lupus, inflammatory bowel disease, Crohn's disease, myasthenia gravis, immunoglobulin nephropathies, myocarditis, autoimmune thyroid disorder, ulcerative colitis, chronic obstructive pulmonary disease, pemphigus vulgaris, or bullous pemphigoid. 
Spoj ili sol za upotrebu prema zahtjevu 22, naznačen time da a) navedena autoimuna bolest predstavlja poremećaj na koži, multiplu sklerozu, reumatoidni artritis, psorijazni artritis, juvenilni artritis, dijabetes tip I, lupus, upalnu bolest crijeva, Crohnovu bolest, mijasteniju gravis, imunoglobulinsku nefropatiju, miokarditis, ili autoimuni poremećaj štitnjače; ili b) navedena autoimuna bolest predstavlja reumatoidni artritis; ili
A compound according to claim 1 wherein at least one of m and r is 1. 
Spoj u skladu sa patentnim zahtjevom 1 naznačen time, da barem jedno od m i r je 1.
Wheat hydrolysate is a plant-derived component, which is part of the medium of the invention based on the fact that cells can also use amino acids that are in peptide form. 
Hidrolizat pšenice je komponenta biljnog podrijetla, i dio je medija predstavljenog izumom temeljem činjenice da biljke mogu koristiti i aminokiseline u obliku peptida.
The process of claim 1, wherein the multi-component gas stream comprises one or more components selected from the group consisting of hydrogen, nitrogen, helium, argon, methane, ethylene, ethane, heavier saturated and unsaturated hydrocarbons and mixtures thereof. 
Proces prema patentnom zahtjevu 9, naznačen time, da višekomponenina plinska struja sadrži jednu ili više komponenata odabranih iz skupine koja se sastoji od vodika, dušika, helija, argona, metana, etilena, etana, težih zasićenih i nezasićenih ugljikovodika i njihovih smjesa.
In vitro release of the active ingredient was determined as in Example 1 and was: Time Released quantity 
Oslobađanje in-vitro djelatne tvari iz pripravka određeno je kao u Primjeru 1 i iznosilo je: Vrijeme
Upon cooling, crystals formed which were collected by filtration, washed with a water:acetonitrile (1:1) solution, and dried. 
Nakon hlađenja su nastali kristali koji su skupljeni filtracijom, isprani otopinom voda:acetonitril (1:1), i osušeni.
identifying the type of symbol in the received transmission signal, according to a same sequence as used in the transmitting system; 
provjere vrste simbola podataka prema istom redoslijedu koji se koristi kod OFDM uređaja za prijenos.
A method as claimed in any one of claims 1 to 4 which further comprises obtaining from said oil a fatty acid-containing fraction. 
Postupak sukladno bilo kojem od zahtjeva 1 do 4, koji nadalje sadrži dobivanje frakcije koja sadrži masne kiseline iz navedenog ulja.
represents a heteroaralkyl or a substituted heteroaralkyl, represents a hydrogen atom, X represents an oxygen atom or a sulfur atom, 
predstavlja heteroaralkil ili supstituirani heteroaralkil; predstavlja atom vodika; X predstavlja atom kisika ili atom sumpora;
the information about a partition type indicates whether a partition type is a symmetric partition type or an asymmetric partition type, and the processor is configured for parsing, from the bitstream, information for determining a maximum size of a coding unit and the split information indicating whether a coding unit is split into smaller coding units, splitting the image into a plurality of maximum coding units according to the information for determining a maximum size of a coding unit, and hierarchically splitting the maximum coding unit among the plurality of maximum coding into the at least one coding unit according to the split information, 
izdvajanje, iz toka bitova, informacije raščlanjivanja koja ukazuje da li je jedinica kodiranja podijeljena u manje jedinice kodiranja i informacije koja ukazuje da li se nesimetrične particije koriste za među-predviđanje; određivanje jedne ili više jedinica kodiranja koje su sadržane u maksimalnoj jedinici kodiranja korištenjem informacije raščlanjivanja; određivanje particija za provođenje među-predviđanja na jedinici kodiranja između jedne ili više jedinica kodiranja, pomoću korištenja informacije koja označava da li se nesimetrične particije za jedinicu kodiranja koriste za među-predviđanje; te provođenje kompenzacije gibanja pomoću particija za jedinicu kodiranja, naznačen time da:
Also disclosed are compounds of Formula (I) 
PATENTNI ZAHTJEVI 1. Spoj formule (I)
The composition of the present invention and its use as a nail restructuring and hardening formulation is illustrated, but not limited to, the following examples. 
Pripravak korišten u ovom izumu i njegova upotreba kao formulacije za restrukturiranje i očvršćivanje nokta ilustrirana je, ali nije ograničena na, slijedećim primjerima.
A compound of general formula (I), or a pro-drug, stereoisomer, pharmaceutically acceptable salt or hydrate thereof, wherein, 
Spoj opće formule (I), ili stereoizomer, farmaceutski prihvatljiva sol ili hidrat istog, pri čemu